Entero Healthcare Q2FY27 Results: Revenue Up 33% YoY to ₹2,087 Cr, EBITDA Jumps 78%
Entero Healthcare Solutions reported Q2FY27 revenue of ₹2,087 Cr, up 33% YoY. EBITDA surged 78% to ₹111 Cr with margins at 5.3%. H1FY27 revenue grew 35% to ₹4,028 Cr, with EBITDA up 85% to ₹208 Cr. The company is on track to meet its full-year guidance.
Significant percentage growth in key financial metrics like revenue and EBITDA, along with margin improvement, is expected to have a high impact on investor sentiment and the company's valuation.
The company reported strong year-on-year growth in revenue, gross profit, EBITDA, and PAT, along with margin expansion, indicating a positive financial performance.
Entero Healthcare Solutions Limited has announced its unaudited financial results for the quarter and half-year ended September 30, 2026. For the second quarter of FY27 (Q2FY27), the company reported a consolidated revenue of ₹2,087.1 crore, marking a significant 33% year-on-year (YoY) increase from ₹1,570.9 crore in Q2FY26. The gross profit for the quarter rose by 49% YoY to ₹240.0 crore, with the gross margin improving by 126 basis points to 11.5%. EBITDA saw a substantial 78% YoY jump to ₹110.7 crore, with the EBITDA margin expanding by 135 basis points to 5.3%. Profit After Tax (PAT) to owners increased by 44% YoY to ₹45.5 crore.
For the first half of FY27 (H1FY27), consolidated revenue grew by 35% YoY to ₹4,027.6 crore. Gross profit increased by 54% YoY to ₹461.3 crore, and EBITDA surged by 85% YoY to ₹207.7 crore. PAT to owners for H1FY27 grew by 41% YoY to ₹83.7 crore.
The company highlighted strong organic growth momentum, outpacing industry growth and sustaining improvement in EBITDA margin. Revenue on a like-for-like (LFL) basis grew by 34.7% YoY in Q2FY27 and 37.2% YoY in H1FY27. Organic revenue growth on an LFL basis was 20.0% YoY for Q2FY27 and 19.8% YoY for H1FY27. The company is on track to meet its full-year guidance. Net Operating Working Capital days were at 64 days for Q2FY27. Return on Capital Employed (RoCE) improved to 22.0% in Q2FY27, and Return on Equity (RoE) was 22.4%. The company also mentioned that operating cash flow for H1FY27 was impacted by timing in trade receivables on a government contract, with collections received in November.
What to do with a filing like this
Entero Healthcare Solutions Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Entero Healthcare Solutions Limited. Read the original for the full detail.